Compare Amylx Pharmaceuticals Inc (AMLX) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Solaredge Technologies Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Solaredge Technologies Inc trades at $54.59 (market cap $3.36B). The key difference: Solaredge Technologies Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | SEDG | |
|---|---|---|
Market Cap | $1.98B | $3.36B |
Sector | Health | Technology |
52-Week High | $18.70 | $78.51 |
52-Week Low | $7.64 | $24.42 |
Enterprise Value | $1.70B | $3.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SolarEdge Technologies (SEDG) trades at $55.18, up 0.77% on the day, with a neutral technical signal and mixed analyst sentiment. The company shows improving operational cash flow ($104M in 2025) but continues to report significant losses (-$405M net income). Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, while solar sector momentum from AI data center demand provides tailwinds.
The stock faces fundamental challenges with negative margins and high debt, though cash flow stabilization and sector growth offer potential upside. Key risks include persistent profitability issues and policy uncertainty, while analyst consensus remains cautious with a $34.99 price target below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
